TRPC6 and pulmonary arterial hypertension: Inhibition of TRPC6 inhibited hypoxia-induced pulmonary vasoconstriction and proliferation and migration phenotypes of PAMSCs, which is a novel therapeutic approach to PAH [41, 42].